UK economy was a bit bigger than thought at end of 2023, ONS says

Britain's Office for National Statistics (ONS) revised its Q4 2023 GDP estimate, now indicating the economy was 2.2% larger than its pre-pandemic peak, up from 1.9%, primarily due to updated calculation methods incorporating multinational companies' overseas production. While this methodological change boosted sectors like pharmaceuticals and manufacturing, the ONS noted minimal impact on overall long-term growth trends, with average annual growth remaining at 1.8%; consequently, the UK's post-pandemic recovery continues to lag behind the Eurozone and U.S., despite the upward revision.

Analysis

The UK's Office for National Statistics (ONS) has upwardly revised its Q4 2023 GDP figure, now estimated to be 2.2% above its pre-pandemic level, compared to the previous 1.9% estimate. This revision is not indicative of a fundamental economic acceleration but is a result of methodological changes, specifically improvements in how research and development and the overseas production of large multinational firms are measured, which has notably boosted the statistical contribution of the pharmaceuticals and manufacturing sectors. Crucially, the ONS itself has stated that these adjustments have a negligible impact on the long-term growth trajectory, with average annual growth since 1998 remaining at 1.8%. Despite the improved headline figure, the UK’s post-pandemic recovery of 4.5% since December 2019 continues to significantly lag behind that of the United States (almost 13%) and the Eurozone (6.0%), underscoring a persistent relative underperformance.

Key Decisions for Investors

• Investors should view the upward GDP revision as a low-impact statistical event, not a signal of strengthening economic momentum, as the underlying long-term growth trend remains unchanged.
• Asset allocation decisions concerning UK exposure should continue to factor in the country's significant growth lag compared to the U.S. and the Eurozone, which this data revision does not alter.
• Monitor specific sectors like pharmaceuticals and manufacturing, which may see revised historical contributions, but focus on forward-looking policy and fundamental economic indicators for future growth catalysts.